Skip to main content

Table 2 Multivariate analyses of HDGF and VEGF

From: Novel HDGF/HIF-1α/VEGF axis in oral cancer impacts disease prognosis

Variable DSSMFSLRFS
CategoryRR95% CIp-valueRR95% CIp-valueRR95% CIp-value
Primary tumor (T)T1-T210.0001*10.0003*   
T31.110.40–3.12 1.090.41–2.88    
T45.982.50–14.33 4.392.00–9.63    
Histological gradeW-D10.0014*10.0009*10.0981
M-D3.091.11–8.62 3.151.20–8.23 1.2470.62–2.48 
P-D7.502.48–22.67 6.702.50–19.60 2.1091.04–4.27 
Nodal status (N)N010.107310.2104   
N12.310.90–5.95 1.770.76–4.10    
N22.981.03–8.58 2.370.88–6.37    
Post-OP CCRTYes1< 0.0001*1< 0.0001*10.0117*
No6.892.90–16.41 5.612.54–12.39 2.0031.17–3.44 
VEGFLow expression10.0183*10.0153*10.0461*
High expression4.091.27–13.15 4.011.30–12.30 2.1001.01–3.45 
HDGF-NLow expression10.0280*10.053410.0285*
High expression3.041.13–8.22 2.360.99–5.62 2.1411.08–4.23 
  1. Post-OP CCRT, postoperative concurrent chemoradiotherapy; W-D, well differentiated; M-D, moderately differentiated; P-D, poorly differentiated; HDGF-N, nuclear expression of hepatoma-derived growth factor; VEGF, vascular endothelial growth factor; DSS, disease-specific survival; MFS, metastasis-free survival; LRFS, local recurrence-free survival; *, Statistical significance